Open-Access Multi-Target Therapeutic Matrix and Prodromal Prevention Framework for Parkinson's Disease and Related Synucleinopathies: Computationally Modelled Combination of Lysosomal Cleansing Agents, Mitochondrial Rescuers, Kinase Inhibitors, Cytop

This open-access defensive publication and prior-art disclosure presents a computationally modeled multi-target therapeutic matrix and prodromal prevention framework for Parkinson’s disease (PD) and related alpha-synucleinopathies. The objective of this disclosure is to establish a dated, publicly accessible prior-art deposit under CC BY 4.0 to dedicated public domain and defensive frameworks. This publication is intentionally designed to reduce opportunities for third parties to establish novelty or inventive step over the concepts, functional combinations, sub-combinations, stoichiometric ranges, phase-staggered administration schedules, and early-stage intervention methodologies disclosed herein. KEY DISCLOSURES & FRAMEWORK HIGHLIGHTS: 1. COMPOSITION OF MATTER & FUNCTIONAL CLASSES:Defensive functional Markush-style definitions, exemplars, bioisosteres, and structural derivatives covering five primary therapeutic mechanism classes plus an optional neurotrophic vector:- Class 1: LRRK2 Kinase Inhibitors & Endo-Lysosomal Trafficking Modulators (e.g., DNL201, DNL151/BIIB122, MLi-2, GNE-0877)- Class 2: Proteinopathy Cleansing & α-Synuclein-Modulating Agents (e.g., Hydralazine, D-penicillamine, N-acetylcysteine, Ambroxol, EGCG)- Class 3: Mitochondrial Rescuers, Mitophagy Promoters & Energy Transport Enhancers (e.g., Urolithin A, Urolithin B, CoQ10, Idebenone, NR, NMN, Cu(ATSM))- Class 4: Cytoprotective & Core Oxidative Stress Neutralizers (e.g., Silibinin, Silybin Phytosome, Curcumin, Resveratrol, Fisetin)- Class 5: Autophagy & Lysosomal Hydrolase Accelerators (e.g., Nilotinib derivatives, Bosutinib, Trehalose, Spermidine, Metformin)- Class 6 (Optional Vector): Neurotrophic & Restorative Factors (e.g., BDNF, GDNF, CDNF, Cerebrolysin, TrkB/RET agonists) 2. STACK VARIATIONS & SUB-COMBINATIONS:Comprehensive disclosure of N-component sub-combinations (N = 2, 3, 4, 5, or 6), including:- 5-Layer Primary Stack: Class 1 + Class 2 + Class 3 + Class 4 + Class 5- 3-Layer Backup Stack A: Class 5 + Class 3 + Class 2 (Nilotinib-Derivative + Urolithin A + Hydralazine)- 3-Layer Backup Stack B: Class 1 + Class 3 + Class 2 (DNL201 + Urolithin A + Hydralazine)- Binary pairs and 4-layer permutations. 3. DOSING RANGES, RATIOS & DELIVERIES:- Stoichiometric molar ratios ranging from 1:1000:1000:1000:1000 to 1000:1:1000:1000:1000 across classes.- Explicit daily dosing ranges (Class 1: 0.1–1000 mg/day; Class 2: 1.0–500 mg/day; Class 3: 10–3000 mg/day; Class 4: 10–2000 mg/day; Class 5: 1.0–800 mg/day).- Delivery modalities including oral, sublingual, intranasal, transdermal, subcutaneous, intravenous, and sustained-release depot formulations. 4. PRODROMAL & PRE-SYMPTOMATIC METHODOLOGY:Discloses intervention timing concepts targeting high-risk pre-symptomatic populations (asymptomatic LRRK2 G2019S, GBA1, SNCA, PINK1, PRKN carriers; Syn-SAA biofluid assay positive individuals; REM Sleep Behavior Disorder / hyposmia cohorts; micro-kinetic wearable monitoring cohorts). 5. IN SILICO QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP):Details dynamic QSP modeling outputs investigating multi-pathway synergy interaction factors (1.18x–1.24x) and simulated motor outcome predictions (UPDRS motor score trajectories) under specific computational parameters. SCIENTIFIC QUALIFICATION & LEGAL DISCLAIMER:This document represents an early-stage computational hypothesis and defensive prior-art disclosure. Numerical outputs, combinations, and simulated mechanisms do not constitute clinical recommendations, proven efficacy, or established drug safety. All therapeutic claims require independent experimental, preclinical, and clinical validation.